Literature DB >> 17575939

[Retrospective analysis of drug treatment on inpatients with chronic heart failure].

Jin-ping Ma1, Lin Wang, Qun Dang, Yong-jian Li, Xi-yuan Li, Cheng-zong Zhang, Guang-ping Li.   

Abstract

OBJECTIVE: To investigate drug treatment of inpatients with chronic heart failure(CHF) during the past 30 years in some areas and to provide more information on the treatment strategy of CHF.
METHODS: In two centers a retrospective study was conducted. All data were taken from the hospitalized cases with chronic heart failure. The medication distributions in different decade, gender, age heart function grade and etiology were analyzed.
RESULTS: 5189 cases were enrolled with the ratio of male to female as 1:1.02. The mean age was (62.93 +/- 13.49) years old. The general causes of chronic heart failure were as follows: coronary heart disease (44.2%), rheumatic heart disease (24.1% ) , pulmonary heart disease (19.0%) and cardiomyopathy (4.8%). The admission cardiac function was mostly seen as grade NYHA IlI and IV, and their proportions were 40.6% and 44.5%. Major medication would include nitride (80.0%), diuretics (71.8% ), digitalis (68.1% ), angiotensin conversion enzyme inhibitors (ACEI) (52.2% ) and beta-blockers (19.5% ) etc. Moreover the frequency of above used medication was essentially increasing decade by decade. The major drug treatment of pulmonary heart disease also included diuretics, nitride, digitalis. ACEI was more commonly used in male than in female cases. The frequency of ACEI and ARB were more commonly used in the group > or = 60 years old than that in the group < 60 years old. The administration frequency of beta- blockers had no significant difference among different age and sexes.
CONCLUSION: The conventional drugs such as nitride, diuretics, digitalis were still dominated the treatment of CHF. Although the administration frequency of ACEI and beta-blockers increased quickly, there had been a great gap between the optimal medical strategy and clinical practice in the management of CHF. Data showed the treatment strategy was changing.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17575939

Source DB:  PubMed          Journal:  Zhonghua Liu Xing Bing Xue Za Zhi        ISSN: 0254-6450


  5 in total

Review 1.  Heart failure in China: a review of the literature.

Authors:  Rinat Ariely; Keith Evans; Tim Mills
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

2.  Burden of heart failure on patients from China: results from a cross-sectional survey.

Authors:  James Ds Jackson; Sarah E Cotton; Sara Bruce Wirta; Catia C Proenca; Milun Zhang; Raquel Lahoz; Frederico J Calado
Journal:  Drug Des Devel Ther       Date:  2018-06-08       Impact factor: 4.162

3.  Quality of Care for Patients Hospitalized for Heart Failure in China.

Authors:  Aakriti Gupta; Yuan Yu; Qi Tan; Shuling Liu; Frederick A Masoudi; Xue Du; Jian Zhang; Harlan M Krumholz; Jing Li
Journal:  JAMA Netw Open       Date:  2020-01-03

Review 4.  Heart failure in East Asia.

Authors:  Yutao Guo; Gregory Y H Lip; Amitava Banerjee
Journal:  Curr Cardiol Rev       Date:  2013-05

5.  Care pathways and treatment patterns for patients with heart failure in China: results from a cross-sectional survey.

Authors:  James Ds Jackson; Sarah E Cotton; Sara Bruce Wirta; Catia C Proenca; Milun Zhang; Raquel Lahoz; Bogdan Balas; Frederico J Calado
Journal:  Drug Des Devel Ther       Date:  2018-07-26       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.